Alligator Bioscience AB (OSTO:ATORX)
kr 0.558 0.012 (2.2%) Market Cap: 422.99 Mil Enterprise Value: 385.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Q2 2021 Alligator Bioscience AB Earnings Call Transcript

Jul 13, 2021 / 11:00AM GMT
Release Date Price: kr3.25 (-1.68%)
Operator

Hello, and welcome to the Alligator Bioscience Q2 report 2021. (Operator Instructions)

Today, I'm pleased to present CEO, Søren Bregenholt; and CFO, Marie Svensson. Please go ahead with your meeting, sir.

SÃ;ren Bregenholt
Alligator Bioscience AB - CEO

¸ -

Yeah. Thank you. Thank you and welcome to this Q2 report call. If we go to the slide, slide number 2, our forward-looking statement. So in slide 3, I'll take you through the significant events in Q2. Most importantly, we at the ASCO meeting on June 4, presented the new encouraging data from our 4-1BB agonistic antibody, ATOR-1017, showing solid proof of mechanism data combined with strong safety data, really giving us a strong belief in the potential of this second-generation 4-1BB agonist in immuno-oncology.

We also recently presented preclinical collaboration data. Our preclinical data from our collaboration with Scandion Oncology, combining our CD40 agonist, mitazalimab with chemotherapy and the Scandion agent in chemo-resistant tumors. From Alligator's point of view, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot